Corbus Pharmaceuticals Holdings, Inc. (CRBP)

US — Healthcare Sector
Peers: LIFE  TRVI  CUE  ANTX  BCAB  KOD  GLMD  AFMD  MREO  ADVM  NXTC  CTMX  NLTX  SPRO  ASMB  ZVSA  OCEA  ZURA  ELEV  ICVX  DAWN  ABOS  XFOR  INZY  VECT 

Automate Your Wheel Strategy on CRBP

With Tiblio's Option Bot, you can configure your own wheel strategy including CRBP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CRBP
  • Rev/Share 0.0
  • Book/Share 10.4167
  • PB 0.8448
  • Debt/Equity 0.0225
  • CurrentRatio 11.821
  • ROIC -0.453

 

  • MktCap 107683840.0
  • FreeCF/Share -4.118
  • PFCF -2.1431
  • PE -2.1353
  • Debt/Assets 0.0204
  • DivYield 0
  • ROE -0.3687

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation CRBP William Blair -- Outperform -- -- Feb. 28, 2025

News

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
CRBP, NVO, SKYE
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive

NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.

Read More
image for news 3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
CRBP
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

NORWOOD, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held June 3-5, 2025 in New York, NY.

Read More
image for news Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
AKTX, CRBP, QURE
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15.

Read More
image for news Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?
CRBP
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Neutral

While CRBP's pipeline shows promise, the company's lack of marketed products remains a concern.

Read More
image for news Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?
3 Unconventional Cannabis Stocks to Watch in 2025
CRBP, JAZZ, PM
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.

Read More
image for news 3 Unconventional Cannabis Stocks to Watch in 2025
Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High?
CRBP
Published: April 18, 2025 by: Zacks Investment Research
Sentiment: Positive

The average of price targets set by Wall Street analysts indicates a potential upside of 764.2% in Corbus Pharmaceuticals (CRBP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Read More
image for news Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High?
After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)
CRBP
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Negative

Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Read More
image for news After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know
CRBP
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Positive

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025
CRBP
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral

NORWOOD, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) (“Corbus” or the “Company”), announced that data from its US and UK conducted first-in-human dose escalation clinical study (“Western study”) of CRB-701 (SYS6002) is being presented today at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).

Read More
image for news CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

About Corbus Pharmaceuticals Holdings, Inc. (CRBP)

  • IPO Date 2014-10-27
  • Website https://www.corbuspharma.com
  • Industry Biotechnology
  • CEO Dr. Yuval Cohen Ph.D.
  • Employees 28

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.